Sotorasib targeted drug price

Sotorasib (Sotorasib) is a new anti-cancer drug that belongs to the category of KRAS G12C inhibitors. KRASGene mutations are common in many cancers, especially in non-small cell lung cancer (NSCLC). Sotoracib is unique in that it is the first treatment to target the KRAS G12C mutation, providing a new treatment option for patients with this specific mutation.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

The KRAS gene is one of the key genes that regulates cell growth and differentiation. When this gene mutates, it causes cells to be unable to regulate their normal growth, leading to the development of cancer. KRAS G12C mutation is the most common form of mutation in the KRAS gene, and the development of sotorasiib is aimed at this mutation.

Sotorasiib blocks the growth signals of cancer cells by specifically inhibiting the KRAS G12C mutation, thus inhibiting tumor development. The development of this drug represents a major breakthrough in the field of cancer treatment, because scientists have long considered directly interfering with the KRAS gene to be an extremely challenging task.

Clinical trial results show that sotoraxib has significant efficacy in some KRAS G12C mutated cancer patients, bringing new hope to this patient group. However, as a new drug, sotoraxib also faces a series of challenges, including the management of side effects and long-term monitoring of efficacy, and requires continuous optimization and improvement in further research and clinical application.